Neuropeptide Y and Stress

Öz

The neurobiological aspects of stress and coping skills has been the focus of interest for many researchers. Some of the studies has shown that there is a significant relationship among genetically variables, stress response and life events. Neuropeptide Y is one of the systems regulating the stress response. Under the prolonged or repeated trauma neuropeptide Y is released from the brain\\\'s key areas. This system shows different levels of functioning in individuals with different levels of resilience. There is particular interest in the variations of genes that encode stress-sensitive signaling molecules during gene-environment interaction. This condition may contribute to susceptibility of stress or stress resilience. Neuropeptide Y system plays a key role in the adap-tation to behavioral stress. The reduced levels of neuropeptide Y have also been observed in treatment-resistant depression and posttraumatic stress disorder. Lower level of neuropeptide Y expression and dysfunctional neuro-peptide Y system in response to stress and resulting decreased stress resilience could increase susceptibility to stress-related disorders.

Anahtar Kelimeler

• Neuropeptide Y, stres, stress resilience

Nöropeptid Y ve Stres İlişkisi

Öz

Stres ve bireysel baş etme yetilerinin nörobiyolojik yönü birçok araştırmacının ilgi odağı olmuştur. Bir dizi çalışmada genetik değişkenler ile strese tepki düzeyleri ve yaşam olayları arasında bir ilişki olduğu gösterilmiştir. Nöropeptid Y stres esnekliğini düzenleyen sistemlerden biridir. Uzun süreli ya da tekrarlayan stres durumlarında nöropeptid Y beynin anahtar bölgelerinden salınır. Bu sistem stresle ilgili bozukluklara yatkınlığı farklı kişilerde farklı esneklikte işleyiş gösterir. Gen-çevre etkileşimleri için özellikle ilgi çekici olan strese duyarlı sinyal moleküllerini kodlayan genlerin değişimidir. Bu durum strese yatkınlığa ya da esnekliğe katkıda bulunabilir. Nöropeptid Y sistemi de strese davranışsal uyumda anahtar rol oynamaktadır. Nöropeptid Y düzeyinin azalmış olması tedaviye dirençli depresyonda ve travma sonrası stres bozukluğunda da gözlenmiştir. Düşük nöropeptid Y ekspresyonunun ya da strese yanıt olarak nöropeptid Y sisteminin yeterince işlevsel olmaması ve sonucunda ortaya çıkan stres esnekliğinin az olması stresle ilişkili bozukluklara yatkınlığı arttırabilmektedir.

Anahtar Kelimeler

• Nöropeptid Y, stres, stres esnekliği

Kaynakça

1. Kilpatrick KL, Williams LM. Potential mediators of post-traumatic stress disorder in child witnesses to domestic violence. Child Abuse Negl 1998; 22:319-330.
2. Bowirrat A, Chen TJ, Blum K, Madigan M, Bailey JA, Chuan Chen AL et al. Neuro- psychopharmacogenetics and neurological antecedents of posttraumatic stress disorder: unlocking the mysteries of resilience and vulnerability. Curr Neuropharmacol 2010; 8:335-358.
3. Bonanno GA. Loss, trauma, and human resilience: Have we underestimated the human capacity to thrive after extremely aversive events? Am Psychol 2004; 59:20-28.
4. Masten AS. Developmental psychopathology as a unifying context for mental health and education models, research, and practice in schools. School Psychol Rev 2003; 32:169-173.
5. Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol 2005; 1:255-291.
6. Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem 2007; 7:1645-1659.
7. Kose S, Gulec MY, Ozalmete OA, Ozturk M, Gulec H, Sayar K. Plasma neuropeptide Y levels in medication naive adolescents with major depressive disorder. Klinik Psikofarmakoloji Bulteni 2010; 20:132-138.
8. Criscione L, Wyss P, Stricker-Krongrad A, Brunner L, Miller J, Crossthwaite A et al. The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 1998; 75- 76:363-371.

9. Gehlert DR. Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides 1999; 33:329-338.
10. Rasmusson AM, Southwick SM, Hauger RL, Charney DS. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha(2) antagonist yohimbine. Neuropsychopharmacology 1998; 19:95-98.
11. Lindner D, van Dieck J, Merten N, Morl K, Gunther R, Hofmann HJ, Beck- Sickinger AG. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochemistry 2008; 47:5905- 5914.
12. Reuss S, Hurlbut EC, Speh JC, Moore RY. Neuropeptide Y localization in telencephalic and diencephalic structures of the ground squirrel brain. Am J Anat 1990; 188:163-174.
13. Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 2002; 26:259-283.
14. Morgan CA, 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry 2000; 47:902-909.
15. Morgan CA, 3rd, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry 2002; 52:136-142.
16. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004; 89:2576-2582.
17. Morgan CA, 3rd, Wang S, Rasmusson A, Hazlett G, Anderson G, Charney DS. Relationship among plasma cortisol, catecholamines, neuropeptide Y, and human performance during exposure to uncontrollable stress. Psychosom Med 2001; 63:412- 422.
18. McCullough LA, Egan TM, Westfall TC. Neuropeptide Y receptors involved in calcium channel regulation in PC12 cells. Regul Pept 1998; 75-76:101-107.
19. Cavadas C, Silva AP, Mosimann F, Cotrim MD, Ribeiro CA, Brunner HR et al. NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab 2001; 86:5956-5963.
20. Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossor MN, Roberts GW et al. Neuropeptide Y distribution in human brain. Nature 1983; 306(5943):584-586.
21. Yıldırım EA, Turhan S. Anksiyete, stres ve yeme davranışında Nöropeptid Y. Düşü- nen Adam 2002; 15:173-181.
22. Dumont Y, Fournier A, St-Pierre S, Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 1993; 13:73-86.
23. Quirion R, Dumont Y, Jacques D, Bouchard P. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J Comp Neurol 1998; 402:372-384.
24. Gehlert DR, Shaw JL, Gackenheimer SL. Functional autoradiography of neuropeptide YY1 and Y2 receptor subtypes in rat brain using agonist stimulated [S- 35]GTP gamma S binding. J Chem Neuroanat 2003; 26:179-193.
25. Gehlert DR, Gackenheimer SL. Differential distribution of neuropeptide Y Y1 and Y2 receptors in rat and guinea-pig brains. Neuroscience 1997; 76:215-224.
26. Jacques D, Tong Y, Shen SH, Quirion R. Discrete distribution of the neuropeptide Y Y5 receptor gene in the human brain: an in situ hybridization study. Brain Res Mol Brain Res 1998; 61:100-107.
27. Fuxe K, Agnati LF, Harfstrand A, Zini I, Tatemoto K, Pich EM et al. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 1983; 118:189-192.
28. Heilig M, Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 1987; 19:221-231.
29. Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 1997; 17:8927- 8936.
30. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear- potentiated startle procedures. Behav Pharmacol 1995; 6:215-222.
31. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004; 38:213-224.
32. Sajdyk TJ, Fitz SD, Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 2006; 9:21-28.
33. Primeaux SD, Wilson SP, Cusick MC, York DA, Wilson MA. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005; 30:1589-1597.
34. Karl T, Burne TH, Herzog H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav Brain Res 2006; 167:87-93.
35. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 2003; 18:143-148.
36. Thiele TE, Marsh DJ, Ste Marie L, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998; 396(6709):366-369.
37. Ehlers CL, Li TK, Lumeng L, Hwang BH, Somes C, Jimenez P et al. Neuropeptide Y levels in ethanol-naive alcohol-preferring and nonpreferring rats and in Wistar rats after ethanol exposure. Alcohol Clin Exp Res 1998; 22:1778-1782.
38. Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007; 30:399-406.
39. Barr CS, Goldman D. Non-human primate models of inheritance vulnerability to alcohol use disorders. Addict Biol 2006; 11:374-385.
40. Suomi SJ. The development of social competence by rhesus monkeys. Ann Ist Super Sanita 1982; 18:193-202.
41. Lindell SG, Schwandt ML, Sun H, Sparenborg JD, Bjork K, Kasckow JW et al. Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 2010; 67:423-431.
42. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008; 452(7190):997-1001.
43. Gelfo F, De Bartolo P, Tirassa P, Croce N, Caltagirone C, Petrosini L et al. Intraperitoneal injection of neuropeptide Y (NPY) alters neurotrophin rat hypothalamic levels: Implications for NPY potential role in stress-related disorders. Peptides 2011; 32:1320-1323.
44. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24:1217-1281.
45. Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997; 132:6-13.
46. Britton KT, Akwa Y, Spina MG, Koob GF. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 2000; 21:37-44.
47. Chee MJ, Myers MG, Jr., Price CJ, Colmers WF. Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus. J Neurosci 2010; 30:3380-3390.
48. Ehlers CL, Somes C, Seifritz E, Rivier JE. CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. Depress Anxiety 1997; 6:1-9.
49. Elfving B, Plougmann PH, Muller HK, Mathe AA, Rosenberg R, Wegener G. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010; 13:563-572.
50. Givalois L, Naert G, Rage F, Ixart G, Arancibia S, Tapia-Arancibia L. A single brain- derived neurotrophic factor injection modifies hypothalamo-pituitary-adrenocortical axis activity in adult male rats. Mol Cell Neurosci 2004; 27:280-295.
51. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 1966; 13:655-669.
52. Hansson AC, Rimondini R, Heilig M, Mathe AA, Sommer WH. Dissociation of antidepressant-like activity of escitalopram and nortriptyline on behaviour and hippocampal BDNF expression in female rats. J Psychopharmacol 2011; doi:10.1177/0269881110393049.
53. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatr Clin Neurosci 2010; 64:341- 357.
54. Naert G, Ixart G, Maurice T, Tapia-Arancibia L, Givalois L. Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress. Mol Cell Neurosci 2011; 46:55-66.
55. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med
56. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R. Neuropeptide-Y and Peptide- Yy as possible cerebrospinal-fluid markers for major depression and schizophrenia, Respectively. J Psychiatr Res 1988; 22:69-79.
57. Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1992; 59:73-80.
58. Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 2000; 47:526-539.
59. Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjogren M et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004; 38:113-121.
60. Mottagui-Tabar S, Prince JA, Wahlestedt C, Zhu G, Goldman D, Heilig M. A novel single nucleotide polymorphism of the neuropeptide Y (NPY) gene associated with alcohol dependence. Alcohol Clin Exp Res 2005; 29:702-707.
61. Lappalainen J, Kranzler HR, Malison R, Price LH, Van Dyck C, Rosenheck RA et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry 2002; 59:825-831.
62. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13:803-811.
63. Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch Gen Psychiatry 1990; 47:548-556.
64. Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetnansky R, Zukowska Z. Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Ann N Y Acad Sci 2008; 1148:232-237.
65. Abe K, Kuo L, Zukowska Z. Neuropeptide Y is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition. Exp Biol Med (Maywood) 2010; 235:1179-1184.
66. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993; 4:285-294.
67. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785-1789.
68. Çelik C, Özdemir B. Esansiyel hipertansiyonda psikolojik etmenler. Psikiyatride Guncel Yaklaşımlar - Current Approaches in Psychiatry 2010; 2:52-65.
69. Gürel Eİ, Pehlivanoğlu B, Bayrak S. Akut stres ile kan akışkanlığı arasındaki ilişki: Cinsiyet ve menstrüel döngü evrelerinin etkisi. Turkiye Klinikleri J Cardiovasc Sci
70. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: Systematic review and meta analysis. Int J Geriatr Psychiatry 2007; 22:613-626.
71. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 2009; 5:e1000318.
72. Ponnapakkam A, Gensure R. Effects of stress after hurricanes Katrina and Rita on pubertal disorders in children. Ochsner J 2008; 8:129-133.
73. Pralong FP, Voirol M, Giacomini M, Gaillard RC, Grouzmann E. Acceleration of pubertal development following central blockade of the Y1 subtype of neuropeptide Y receptors. Regul Pept 2000; 95:47-52.
74. Dieguez C, Page MD, Scanlon MF. Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol (Oxf) 1988; 28:109-143.
75. Stratakis CA, Gold PW, Chrousos GP. Neuroendocrinology of stress: implications for growth and development. Horm Res 1995; 43:162-167.
76. Powell GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Engl J Med 1967; 276:1279-1283.
77. Reinhart JB, Drash AL. Psychosocial dwarfism: Environmentally induced recovery. Psychosom Med 1969; 31:165-172.
78. Saenger P, Levine LS, Wiedemann E, Schwartz E, Korth-Schutz S, Pareira J et al. Somatomedin and growth hormone in psychosocial dwarfism. Padiatr Padol Suppl 1977; (5):1-12.
79. Stanhope R, Wilks Z, Hamill G. Failure to grow: Lack of food or lack of love? Prof Care Mother Child 1994; 4:234-237.
80. Armario A, Marti O, Gavalda A, Giralt M, Jolin T. Effects of chronic immobilization stress on GH and TSH secretion in the rat: response to hypothalamic regulatory factors. Psychoneuroendocrinology 1993; 18:405-413.
81. Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, Vittone B et al. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 1992; 6:101-118.
82. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 2000; 143:1-13.
83. Van den Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 2002; 23:370-391.
84. Van den Berghe G, Shalet SM. Critical illness as a model of hypothalamic ageing. Novartis Found Symp 2002, 242:205-215.
85. Puybasset L, Lacolley P, Laurent S, Mignon F, Billaud E, Cuche JL et al. Effects of clonidine on plasma catecholamines and neuropeptide Y in hypertensive patients at rest and during stress. J Cardiovasc Pharmacol 1993; 21:912-919.
86. Zukowska-Grojec Z, Konarska M, McCarty R. Differential plasma catecholamine and neuropeptide Y responses to acute stress in rats. Life Sci 1988; 42:1615-1624.
87. Zukowska-Grojec Z, Dayao EK, Karwatowska-Prokopczuk E, Hauser GJ, Doods HN. Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors. Am J Physiol 1996; 270:H796-800.
88. Zhang WG, Lundberg JM, Thoren P. Neuropeptide Y Y1 receptor antagonist (BIBP 3226) attenuates stress evoked tachycardia in conscious spontaneously hypertensive rats. Cardiovasc Drug Ther 1997; 11:801-806.
89. Al-Ayadhi LY. Neurohormonal changes in medical students during academic stress. Ann Saudi Med 2005; 25:36-40.
90. Castagne V, Corder R, Gaillard R, Mormede P. Stress-induced changes of circulating Neuropeptide-Y in the rat: Comparison with catecholamines. Regul Pept 1987; 19:55-63.
91. Rybkin II, Zhou Y, Volaufova J, Smagin GN, Ryan DH, Harris RBS. Effect of restraint stress on food intake and body weight is determined by time of day. Am J Physiol 1997; 273:R1612-R1622.
92. Rice RW, Abe K, Critchlow V. Abolition of plasma growth hormone response to stress and of the circadian rhythm in pituitary-adrenal function in female rats with preoptic-anterior hypothalamic lesions. Brain Res 1978; 148:129-141.
93. Critchlow V, Abe K, Urman S, Vale W. Effect of lesions in the periventricular nucleus of the preoptic-anterior hypothalamus on growth hormone and thyrotropin secretion and brain somatostatin. Brain Res 1981; 222:267-276.
94. Adams EF, Venetikou MS, Woods CA, Lacoumenta S, Burrin JM. Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours. Acta Endocrinol (Copenh) 1987; 115:149-154.
95. Barb CR, Barrett JB. Neuropeptide Y modulates growth hormone but not luteinizing hormone secretion from prepuberal gilt anterior pituitary cells in culture. Domest Anim Endocrinol 2005; 29:548-555.
96. Bluet-Pajot MT, Epelbaum J, Gourdji D, Hammond C, Kordon C. Hypothalamic and hypophyseal regulation of growth hormone secretion. Cell Mol Neurobiol 1998; 18:101-123.
97. Park S, Sohn S, Kineman RD. Fasting-induced changes in the hypothalamic- pituitary-GH axis in the absence of GH expression: lessons from the spontaneous dwarf rat. J Endocrinol 2004; 180:369-378.
98. Bacchi F, Mathe AA, Jimenez P, Stasi L, Arban R, Gerrard P et al. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006; 27:3202-3207.
99. Noe F, Frasca A, Balducci C, Carli M, Sperk G, Ferraguti F et al. Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 2009; 6:300-306.
100. Noe F, Vaghi V, Balducci C, Fitzsimons H, Bland R, Zardoni D et al. Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther 2010; 17:643-652.
101. Sperk G, Hamilton T, Colmers WF. Neuropeptide Y in the dentate gyrus. Prog Brain Res 2007; 163:285-297.
102. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259(5094):528-531.
103. Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA et al. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 2011; 21:233-238.
104. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001; 410(6831):940-944.
105. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999; 368:143-147.
106. Sorensen G, Lindberg C, Wortwein G, Bolwig TG, Woldbye DP. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 2004; 77:723-729.
107. Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A et al. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 1998; 19:359-363.
108. Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2010; 2:429-439.
109. Monks SA, Karagianis G, Howlett GJ, Norton RS. Solution structure of human neuropeptide Y. J Biomol NMR 1996; 8:379-390.
110. Murat Gülsün, Doç. Dr., Isparta Asker Hastanesi, Isparta; Lut Tamam, Prof. Dr., Çukurova Üniv. Tıp Fakültesi
111. Psikiyatri ABD, Adana; Fatih Özçelik, Uzm. Dr., Gümüşsuyu Asker Hastanesi, İstanbul